rapporto attivita - Istituto di Ricerche Farmacologiche Mario Negri

IRFMN
Dynamic contour tonometry and Goldmann applanation tonometry: correlation with intracameral assessment of
intraocular pressure
Eur J Ophthalmol 2011 E-pub
Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, Damia G, Ganzinelli M, Marangon E,
Sala F, Clivio L, Chiorino G, Di Giandomenico S, Rocchi M, Capozzi O, Margison G P, Watson A J,
Caccuri A M, Pastore A, Fossati A, Mantovani R, Grosso F, Tercero J C, Erba E, D'Incalci M
Characterization of a new trabectedin resistant myxoid liposarcoma cell line that shows collateral sensitivity to
methylating agents
Int J Cancer 2011 E-pub
Banzi R, Torri V, Bertele' V, Garattini S
Antibiotics versus surgery for appendicitis
Lancet 2011 378 : 1067-1068
Gori S, Greco M T, Catania C, Colombo C, Apolone G, Zagonel V, AIOM Group
A new informed consent form model for cancer patients: Preliminary results of a prospective study by the Italian
Association of Medical Oncology (AIOM)
Patient Educ Couns 2011 E-pub
Lazzari C, Spreafico A, Bachi A, Roder H, Floriani I, Garavaglia D, Cattaneo A, Grigorieva J, Vigano M
G, Sorlini C, Ghio D, Tsypin M, Bulotta A, Bergamaschi L, Gregorc V
Changes in plasma mass-spectral profile in course of
treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors
J Thorac Oncol 2011 E-pub
Cervo L, Torri V
Comment on: "Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in
mice" (Magnani P, Conforti A, Zanolin E, Marzotto M and Bellavite P, Psychopharmacology, 2010)
Psychopharmacology (Berl) 2011 E-pub
Gaafar R M, Surmont V F, Scagliotti G V, Van Klaveren R J, Papamichael D, Welch J J, Hasan B, Torri
V, van Meerbeeck J P, EORTC Lung Cancer Group, Italian Lung Cancer Project
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced
NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)
Eur J Cancer 2011 47 : 2331-2340
Corli O
Breakthrough cancer pain: from definition to clinical features
Int J Palliat Nurs 2011 17 n. 9 Suppl : 1-3
Previdi S, Abbadessa G, Dalò F, France D S, Broggini M
Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivatinib (ARQ
197) and shRNA c-MET knockdown
Mol Cancer Ther 2011 E-pub
Damia G, Broggini M, Marsoni S, Venturini S, Generali D
New omics information for clinical trial utility in the primary setting
J Natl Cancer Inst Monogr 2011 43 : 128-133
Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller W R, Untch
M, Sotiriou C, Daidone M, Conte P F, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P,
Dowsett M, Desmedt C, Mansel R E, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H,
Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tempellini M, Dontu G,
Van't Veer L, Harris A L, Fox S B, Dogliotti L, Bottini A
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of
the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy
(2010)
J Natl Cancer Inst Monogr 2011 43 : 147-151
38
RAPPORTO ATTIVITA’ 2011